Prosecution Insights
Last updated: October 25, 2026

Mccarter & English, LLP

Technology area: Biotechnology & Pharmaceuticals

167 pending office actions • 35 clients • 152 examiners • 102 art units • 13 of 167 (8%) have an AI response strategy ready • 7 patents granted in the last 365 days

Analysis

This profile covers Biotechnology & Pharmaceuticals and includes 9403 career applications. The resolved allowance rate is 86.87%, while the average is 4.55 office actions per allowance. The historical record is broad and shows favorable reported allowance outcomes, with multiple examination events commonly occurring before allowance.

The profile has 169 pending office actions, indicating a substantial active docket alongside the completed application record. Practitioners can use the action average to anticipate sustained prosecution activity and the allowance rate to frame historical outcomes. The pending workload also calls for systematic tracking of response deadlines, claim amendments, and recurring examiner issues across this technology area.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=9403 apps, methodology: how we score firms)

86.9%
Allowance Rate
n=9403
+0.45σ
Allowance Rate (norm)
n=9403
4.6
OAs to Allowance
n=7022
+0.64σ
OAs to Allow (norm)
n=7022
1255 days
Time to Allowance
n=7022
+6.9pp
Interview Lift
n=9403
37.2%
RCE Rate
n=9403
2.2%
Appeal Rate
n=9403

Rejection Performance (% of received rejections ultimately overcome)

87.9%
§101 Overcome
n=1827
84.8%
§102 Overcome
n=3299
86.2%
§103 Overcome
n=5389
88.2%
§112 Overcome
n=2883

Specialization & Scale

H04W, H04L, G06F
Top CPC Subclasses
34%
Top-3 CPC Share
n=9403
50
Practitioners
n=9403
188.1
Apps / Practitioner
n=9403

Portfolio Summary

167
Total Pending OAs
113
Non-Final OAs
46
Final Rejections
8
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 51 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

29
Overdue
0
Due this week
7
Due this month
8
Due in next 60 days
7
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 51 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (29)Due ≤ 30 days (7)Due ≤ 60 days (8)Due later (7)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

63
Hard (38%)
87
Medium (52%)
14
Easy (8%)
3
Unknown (2%)

Rejection Statute Mix

BucketCases
§101 only6 (4%)
§101 + other9 (5%)
§103 only61 (37%)
§102 only9 (5%)
§112 only9 (5%)
Double-patenting only5 (3%)
Double-patenting + other17 (10%)
Multi-statute (no §101)48 (29%)
No statute on record3 (2%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

71
Life Sciences
43% of docket
28
Information Tech
17% of docket
32
Communications
19% of docket
7
Semiconductors
4% of docket
29
Mechanical / Eng
17% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

1,670 h
Manual time on pending OAs
334 h
Time saved (low, 20%)
584 h
Time saved (mid, 35%)
14.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HUDSON, AMY ROSE 5 74.8% +11.7%
TRAN, CHRISTINA L 3 51.6% +49.8%
WHITE, DAWANNA SHAR-DAY 2 62.4% +24.3%
RICCI, CRAIG D 2 53.7% +52.6%
KIFLE, BRUCK 2 79.3% +15.8%
SHAH, NILAY J 2 76.3% +46.9%
VYAS, KEYUR ANILKUMAR 2 50.0% +58.7%
XU, XIAOYUN 2 59.9% +31.6%
GIBBS, TERRA C 2 63.7% +10.4%
YU, DELPHINUS DOU YI 2 33.3% +0.0%

Hard Cases (63)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17221021 Core-Shell Particles and Composite Material Synthesized Therefrom CROWELL, ANNA M 100d overdue
17580279 Systems and Methods for Roof Area and Slope Estimation Using a Point Set DRAPEAU, SIMEON PAUL 60d overdue
18672139 Spatial Audio Parameter Merging ZHANG, LESHUI 59d overdue
16250194 Method of Making a Ceramic Matrix Composite EMPIE, NATHAN H 25d overdue
18412677 Acoustic Echo Cancellation ROBERTS, SHAUN A 22d overdue
18367222 Apparatus, Methods, and Computer Programs WELTE, BENJAMIN PETER 8d overdue
17886279 PEN-TYPE DRUG INJECTION DEVICE WITH CONTROLLER AND TIME LOCK-OUT MECHANISM FOR ITS DRIVE FARRAR, LAUREN PENG 14d
18373344 Apparatus, Method and Computer Program CHOI, WON JUN 15d

Interview Candidates (22)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17683423 XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF HUDSON, AMY ROSE 110d overdue
18456718 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE RICCI, CRAIG D 99d overdue
18324191 METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION TRAN, CHRISTINA L 52d overdue
18376217 TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF HUDSON, AMY ROSE 38d overdue
17974596 APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF TRAN, CHRISTINA L 4d overdue
17870368 NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY XU, XIAOYUN 55d
18581511 BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF VYAS, KEYUR ANILKUMAR 79d
18852579 T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF WHITE, DAWANNA SHAR-DAY —

Client Portfolio (35 clients)

Top Art Units

Art UnitApps
163712
16369
37836
16254
16354
17974
37533
26443
16263
16293

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19361469 Generative Artificial Intelligence Systems and Methods for Processing Insurance Underwriting Data Insurance Services Office, Inc. SUBRAMANIAN, NARAYANSWAMY 3691 §101§103 Non-Final OA — Pending Oct 17, 2025
19473351 SIGNALING INFORMATION ABOUT MULTIPLE POST PROCESSING FILTERS Nokia Technologies Oy KIR, ALBERT 2485 §103 Non-Final OA — Pending Oct 07, 2025
19469643 SYSTEMS AND METHODS FOR CONTROLLING ELASTIC CABLE DRIVEN ROBOT JOINTS Vicarious Surgical Inc. NGUYEN, ROBERT T 3619 §102§103§112 Non-Final OA — Pending Sep 26, 2025
19165429 CONTEXT ADAPAPTIVE BINARY ARITHMETIC CODING INITIALIZATION FOR GRADUAL DECODER REFRESH PICTURES Nokia Technologies Oy SENFI, BEHROOZ M 2482 §102§103 Non-Final OA — Pending Sep 15, 2025
19292378 AUDIO AND VISUAL MODIFICATION Nokia Technologies Oy LAMB, CHRISTOPHER RAY 2622 §102§103 Final Rejection — Pending Aug 06, 2025
19276784 Y-Check Valves, Related Components, and Related Methods Hayward Industries, Inc. GARDNER, NICOLE 3753 §103 Non-Final OA — Pending Jul 22, 2025
19239108 Computer Vision Systems and Methods for Modeling Roofs of Structures Using Two-Dimensional and Partial Three-Dimensional Data Insurance Services Office, Inc. CHIN, MICHELLE 2614 Other Non-Final OA — Pending Jun 16, 2025
19234365 Physical Downlink Control Channel Monitoring for Inter-Cell Beam Management Nokia Technologies Oy HAQUE, ABUSAYEED M 2466 §103 Non-Final OA — Pending Jun 11, 2025
19227130 CHROMA MOTION VECTOR REFINEMENT USING RECONSTRUCTED LUMA OR CHROMA Nokia Technologies Oy MCFALL, CHRISTIAN PAUL 2426 §102§103 Final Rejection — Pending Jun 03, 2025
19213295 System and Method for Generating Simulated Scenes from Open Map Data for Machine Learning Insurance Services Office, Inc. VU, KHOA 2611 DP Non-Final OA — Pending May 20, 2025
19207145 SURGICAL VIRTUAL REALITY USER INTERFACE Vicarious Surgical Inc. BROWN, SHEREE N 2612 §102 Non-Final OA — Pending May 13, 2025
19189968 Method, Apparatus and Computer Program Nokia Technologies Oy PHUONG, DAI 2644 §103DP Non-Final OA — Pending Apr 25, 2025
19092387 Lighting System For An Environment And A Control Module For Use Therein Hayward Industries, Inc. CHAI, RAYMOND REI-YANG 2845 §103Other Non-Final OA — Pending Mar 27, 2025
19075995 Material-Handling Robot With Magnetically Guided End-Effectors Persimmon Technologies Corporation KC, SAGAR 3657 §103 Non-Final OA — Pending Mar 11, 2025
19073878 Machine Learning Systems and Methods for Automatic Photo Labeling and Filing Xactware Solutions, Inc. LU, ZHIYU 2665 §102 Non-Final OA — Pending Mar 07, 2025
19066412 DYNAMIC CLAMPS AND METHODS OF USE THEREOF Praxis Precision Medicines, Inc. JACKSON-TONGUE, LAKIA J 1645 §102§112 Non-Final OA — Pending Feb 28, 2025
19062827 GENERATING GRAPHICAL REPRESENTATIONS FOR VIEWING 3D DATA AND/OR IMAGE DATA Faro Technologies, Inc. RICHER, AARON M 2617 §103 Final Rejection 44d overdue Pending Feb 25, 2025
19057507 MICROCHIP CAPILLARY ELECTROPHORESIS ASSAYS AND REAGENTS Regeneron Pharmaceuticals, Inc. BALL, JOHN C 1795 §103§112Other Non-Final OA — Pending Feb 19, 2025
19055929 Computer Vision Systems and Methods for Automatically Detecting, Classifying, and Pricing Objects Captured in Images or Videos Insurance Services Office, Inc. AKINYEMI, AJIBOLA A 2649 §102§103 Non-Final OA — Pending Feb 18, 2025
19036389 Machine Learning Systems and Methods for Automatic Construction Scheduling and Expense Estimation Xactware Solutions, Inc. DIVELBISS, MATTHEW H 3624 §101§102§103 Non-Final OA — Pending Jan 24, 2025
19009453 Compact Universal Gas Pool Heater And Associated Methods Hayward Industries, Inc. BAKER, LORI LYNN 3754 §101 Non-Final OA — Pending Jan 03, 2025
18879994 METHOD APPARATUS AND COMPUTER PROGRAM PRODUCT FOR SIGNALING BOUNDARY VERTICES Nokia Technologies Oy OAKES, JUSTIN MONTGOMERY 2662 §103 Non-Final OA — Pending Dec 30, 2024
18973911 Computer Vision Systems and Methods for Generating Building Models Using Three-Dimensional Sensing and Augmented Reality Techniques Insurance Services Office, Inc. WILSON, NICHOLAS R 2611 DP Non-Final OA — Pending Dec 09, 2024
18953925 HYDRODYNAMIC FOCUSING APPARATUS AND METHODS Cytonome/St, LLC CHAUDRY, ATIF H 3753 §103 Final Rejection 45d overdue Pending Nov 20, 2024
18953486 Computer Vision Systems and Methods for Detecting Structures Using Aerial Imagery and Heightmap Data Insurance Services Office, Inc. COUSO, JOSE L 2667 §102§103 Non-Final OA — Pending Nov 20, 2024
18864098 METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS Praxis Precision Medicines, Inc. JACKSON, SHAWQUIA 1626 §102 Non-Final OA — Pending Nov 08, 2024
18941023 MICROORGANISMS ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA Synlogic Operating Company, Inc. GANGLE, BRIAN J 1645 §112DP Non-Final OA — Pending Nov 08, 2024
18864351 CRYSTALLINE POLYMORPHS OF N-METHYL-N-((1S,3S)-3-METHYL-3-((6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRAZIN-4-YL)OXY)CYCLOBUTYL)ACRYLAMIDE BIOGEN MA INC. NEAGU, IRINA 1629 §102§112DP Non-Final OA — Pending Nov 08, 2024
18930698 DERIVATION OF INTRA PREDICTION MODE MODES USING CONTENT ANALYSIS Nokia Technologies Oy HOLDER, ANNER N 2484 §102 Final Rejection — Pending Oct 29, 2024
18927451 TREATMENT OF NEUROLOGICAL DISORDERS Praxis Precision Medicines, Inc. VALENROD, YEVGENY 1628 §103Other Non-Final OA — Pending Oct 25, 2024
18913485 SYSTEMS AND METHODS FOR PATIENT TUMOR-IMMUNE PHENOTYPING FROM IMMUNOFLUORESCENCE (IF) IMAGE ANALYSIS Sanofi ZHENG, JACKY X 2681 §101 Non-Final OA — Pending Oct 11, 2024
18852579 T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF Praxis Precision Medicines, Inc. WHITE, DAWANNA SHAR-DAY 1627 §102§103§112 Non-Final OA — Pending Sep 30, 2024
18852396 T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND METHODS OF USE THEREOF Praxis Precision Medicines, Inc. RICCI, CRAIG D 1611 §102§103 Non-Final OA — Pending Sep 27, 2024
18882884 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS Agios Pharmaceuticals, Inc. KIFLE, BRUCK 1624 DP Non-Final OA — Pending Sep 12, 2024
18830643 ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF Regeneron Pharmaceuticals, Inc. BOESEN, AGNIESZKA 1672 §112 Non-Final OA — Pending Sep 11, 2024
18845099 METHOD AND APPARATUS FOR TRANSMITTING FEEDBACK DURING WIRELESS COMMUNICATION Nokia Technologies Oy RAHMAN, SHAH M 2413 §102§103 Non-Final OA — Pending Sep 09, 2024
18826782 METHOD OF OPERATING A LARGE-VOLUME DELIVERY DEVICE Sanofi-Aventis Deutschland GmbH GOLOVAN, MARK 3783 §102§103§112 Non-Final OA — Pending Sep 06, 2024
18826573 DRIVE MECHANISM FOR LARGE VOLUME DELIVERY DEVICE Sanofi-Aventis Deutschland GmbH KASHYAP, ESHA PRAKASH 3783 §102§103§112 Non-Final OA — Pending Sep 06, 2024
18826562 METHOD OF ASSEMBLING A LARGE VOLUME DELIVERY DEVICE Sanofi-Aventis Deutschland GmbH SHUTTY, DAVID G 3731 §103§112 Non-Final OA — Pending Sep 06, 2024
18817728 MULTI-CHANNEL RADIO TRANSCEIVER Nokia Technologies Oy TSE, YOUNG TOI 2632 §102§103§112 Final Rejection — Pending Aug 28, 2024
18816013 Multi-Cell Positioning Nokia Technologies Oy BATAILLE, FRANTZ 2681 §103 Non-Final OA — Pending Aug 27, 2024
18841428 Steel Wire and Spring with Excellent Antibacterial Properties and Corrosion Resistance and Method for Manufacturing the Same Scherdel Innotec Forschungs- Und Entwicklungs- GmbH KRUPICKA, ADAM C 1784 §103 Non-Final OA — Pending Aug 26, 2024
18841619 PDCCH MONITORING IN CARRIER AGGREGATION DEPLOYMENT Nokia Technologies Oy AMBAYE, MEWALE A 2469 §103 Non-Final OA — Pending Aug 26, 2024
18811440 Systems and Methods for Machine Learning From Medical Records Insurance Services Office, Inc. EZEWOKO, MICHAEL I 3682 §101§102§103 Non-Final OA — Pending Aug 21, 2024
18809785 Check Valve With Integral Handle Hayward Industries, Inc. TIETJEN, MARINA ANNETTE 3799 §102 Non-Final OA — Pending Aug 20, 2024
18809768 System and Method for Creating Customized Insurance-Related Forms Using Computing Devices Insurance Services Office, Inc. MERCADO VARGAS, ARIEL 2118 §103Other Non-Final OA — Pending Aug 20, 2024
18837245 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. WHITE, DAWANNA SHAR-DAY 1627 §112 Non-Final OA — Pending Aug 09, 2024
18791929 Machine Learning Systems and Methods for Image Splicing Detection and Localization Insurance Services Office, Inc. VANCHY JR, MICHAEL J 2666 §103 Non-Final OA — Pending Aug 01, 2024
18834785 DGK TARGETING COMPOUNDS AND USES THEREOF Arvinas Operations, Inc. SEAMAN, D MARGARET M 1625 §102§112 Non-Final OA — Pending Jul 31, 2024
18788444 Methods for NW-Sided Model Data Collection with Low Measurement Reporting Overhead Nokia Technologies Oy HAILEGIORGIS, FITWI Y 2632 §103 Non-Final OA 41d Pending Jul 30, 2024

View all 167 →

Managing Mccarter & English, LLP's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

What is Mccarter & English, LLP's patent allowance rate?

86.9% of resolved applications prosecuted by Mccarter & English, LLP were allowed, across 9,403 applications in USPTO records.

How many office actions does Mccarter & English, LLP average before allowance?

4.55 office actions per allowed application on average.

How many pending office actions does Mccarter & English, LLP have?

167 pending office actions as of October 2026, for 35 clients, before 152 examiners in 102 art units.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month